Key result
App-based biofeedback reduces monthly migraine days by ~1 day versus waitlist control.
Why the study?
The study was conducted to evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine.
Does app-based self-administered biofeedback reduce monthly migraine days in adults with episodic migraine?
RCT (n=279)
Open-label
randomized
Yes
Does app-based self-administered biofeedback reduce monthly migraine days in adults with episodic migraine?
Mean Difference: 0.9 (95% CI 0.3–1.5)
Absolute Event Rate: -0.9% vs 0%
p-value: p=0.002
App-based self-administered biofeedback significantly reduces migraine frequency and improves quality of life in adults with episodic migraine.
No takes yet. Share an insight, caveat, or question.
Opens a scalable nonpharmacologic option for episodic migraine; provides first RCT evidence for fully self-administered app biofeedback.
Poole et al. (2026) conducted an RCT in episodic migraine (n=279). App-based self-administered biofeedback vs. waitlist control was evaluated on change in monthly migraine days (MMDs) from baseline to weeks 9–12 (MD 0.9, 95% CI 0.3 to 1.5, p=0.002). App-based self-administered biofeedback significantly reduced monthly migraine days compared to waitlist control (mean difference 0.9 days; 95% CI 0.3-1.5; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: